DEA Archived Press Releases

Press Releases before January 20, 2025
5 Results - Showing 1 to 5
PRESS RELEASE

Administrator Anne Milgram Remarks on the Overdose Epidemic

Thank you and good morning. Thank you to ONDCP and to all the federal partners with whom we have been working on this important issue. This is a critical moment in our country. DEA’s mission is to keep American communities safe and healthy and we are in the midst of...
PRESS RELEASE

DEA Issues Public Safety Alert on Sharp Increase in Fake Prescription Pills Containing Fentanyl and Meth

Newark, N.J. – Today, the Drug Enforcement Administration issued a Public Safety Alert warning Americans of the alarming increase in the lethality and availability of fake prescription pills containing fentanyl and methamphetamine. DEA’s Public Safety Alert, the first in six years, seeks to raise public awareness of a significant nationwide...
PRESS RELEASE

DEA 2020 Year in Review: Combatting Serious Drug-Related Threats During the Pandemic

WASHINGTON – With the unprecedented worldwide health emergency brought on by COVID-19, last year was filled with new challenges and increased risks. While much of the world focused on combating the pandemic, DEA continued to implement initiatives to combat violent drug traffickers who were intent on flooding cities and rural...
PRESS RELEASE

DEA acts against dangerous, deadly designer synthetic drug linked to 151 overdose deaths since 2015

WASHINGTON – The Drug Enforcement Administration today announced action against a dangerous designer synthetic cathinone linked to 151 overdose deaths in the United States between 2015 and 2018. Published in today’s Federal Register, DEA’s action puts N-Ethylpentylone into Schedule I of the Controlled Substances Act. Schedule I substances refer to...
PRESS RELEASE

Justice Department, DEA propose significant opioid manufacturing reduction in 2019

WASHINGTON – The Department of Justice and U.S. Drug Enforcement Administration have proposed a reduction for controlled substances that may be manufactured in the U.S. next year. Consistent with President Trump’s “Safe Prescribing Plan” that seeks to “cut nationwide opioid prescription fills by one-third within three years,” the proposal decreases...